

Haematologica
HAEMATOL/2018/207027
Version 3

New molecular and therapeutic insights into canine diffuse large B cell lymphoma elucidates the role of the dog as a model for human disease

Luca Aresu, Serena Ferraresso, Laura Marconato, Luciano Cascione, Sara Napoli, Eugenio Gaudio, Ivo Kwee, Chiara Tarantelli, Andrea Testa, Chiara Maniaci, Alessio Ciulli, Petra Hillmann, Thomas Bohnacker, Matthias P. Wymann, Stefano Comazzi, Massimo Milan, Fulvio Riondato, Giulia Dalla Rovere, Mery Giantin, Diana Giannuzzi, and Francesco Bertoni

Disclosures: Alessio Ciulli: scientific founder, director and shareholder of Amphista Therapeutics; institutional research funds from Boehringer Ingelheim and Nurix, Inc. Petra Hillmann is an employee of at PIQUR Therapeutics AG. M.P. Wymann is an employee of and has ownership interests (including patents) at PIQUR Therapeutics AG. Francesco Bertoni: institutional research funds from Acerta, ADC Therapeutics, Bayer AG, Cellestia, CTI Life Sciences, EMD Serono, Helsinn, ImmunoGen, Menarini Ricerche, NEOMED Therapeutics 1, Oncology Therapeutic Development, PIQUR Therapeutics AG; consultancy fee from Helsinn, Menarini; expert statements provided to HTG; travel grants from Amgen, Astra Zeneca, Jazz Pharmaceuticals, PIQUR Therapeutics AG.

Contributions: LA, SF and FB conceived and designed the study. LM, FR and SC acquired clinical data and follow up. SF, MM, GDR acquired all genomic and transcriptomic data, SN, EG and CT performed in vivo and in vitro experiments. SF, GDR, DG, MG and MM performed raw data preprocessing. LA, LC, IK and FB performed statistical and computational analyses. AT, CM, AC, PH, TB, MPW synthesized and provide compounds. LA and FB wrote the paper. All authors discussed the results and implications and edited the manuscript.